Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Neoprobe

This article was originally published in The Gray Sheet

Executive Summary

Neoprobe: Adopts pre-emptive shareholder rights plan designed to protect the interests of its shareholders in the event of a "coercive or unfair takeover" attempt. Under the plan, one right will be distributed for each share of common stock on Aug. 28. "Each right entitles stockholders to purchase one-hundredth of a share of a special series of preferred stock at an exercise price of $35," the firm states. The exercise price could be modified "if someone acquires or tenders for 15% or more of the company's common stock." Neoprobe is developing its RIGS system for diagnosis and treatment of cancer ("The Gray Sheet" April 10, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004480

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel